Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 9/20 | 0.88 |
| ▸ | ADORA3 | P0DMS8 | 7/20 | 0.88 |
| ▸ | ADORA1 | P30542 | 7/20 | 0.88 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.88 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.88 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.88 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.88 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.88 |
| ▸ | TSHR | P16473 | 1/20 | 0.88 |
| ▸ | MEN1 | O00255 | 1/20 | 0.88 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.88 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.88 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.88 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.87 |
| ▸ | ATM | Q13315 | 1/20 | 0.87 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13259762 | 1.00 | ADORA2A (0.88) | ADORA2AADORA3ADORA1ADORA2BKDM4E | |
| SCHEMBL8923545 | 1.00 | ADORA2A (0.88) | ADORA2AADORA3ADORA1ADORA2BKDM4E | |
| SCHEMBL10089214 | 1.00 | ADORA2A (0.88) | ADORA2AADORA3ADORA1ADORA2BKDM4E | |
| Cgs-21680 SCHEMBL19807521 | 0.94 | ADORA2A (1.00) | ADORA2AADORA3ADORA1ADORA2BKDM4E | |
| Cgs-21680 SCHEMBL724684 | 0.94 | ADORA2A (1.00) | ADORA2AADORA3ADORA1ADORA2BKDM4E | |
| Cgs-21680 SCHEMBL24178317 | 0.94 | ADORA2A (1.00) | ADORA2AADORA3ADORA1ADORA2BKDM4E | |
| Cgs-21680 SCHEMBL12648395 | 0.94 | ADORA2A (1.00) | ADORA2AADORA3ADORA1ADORA2BKDM4E | |
| Cgs-21680 SCHEMBL2318561 | 0.94 | ADORA2A (1.00) | ADORA2AADORA3ADORA1ADORA2BKDM4E | |
| SCHEMBL20615307 | 0.94 | ADORA2A (0.88) | ADORA2AADORA3ADORA1ADORA2BKDM4E | |
| Cgs-21680 SCHEMBL724685 | 0.94 | ADORA2A (1.00) | ADORA2AADORA3ADORA1ADORA2BKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188063-B2 | A2A receptor agonists for the central nervous system; antiinflammatory agents; 2,7-disubstituted-5-amino-pyrazolo[4,3-e]-[1,2,4]-triazolo[1,5-c]pyrimidines, mefloquine, 8-(3-chlorostyryl)caffeine, 3,7,8-trisubstituted-1-propargyl-xanthines; 2,5-disubstituted-7-amino-[1,2,4]triazolo[1,5-a][1,3,5]triazines | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2012-05-29 | — | — | US | disclosed |
| US-20110166094-A1 | AGONISTS OF A2A ADENOSINE RECEPTORS FOR TREATING RECURRENT TUMOR GROWTH | PGXHEALTH, L.L.C. (US) | 2011-07-07 | — | — | US | disclosed |
| US-20080312160-A1 | METHOD OF TREATING ENTERITIS, INTESTINAL DAMAGE, AND DIARRHEA FROM C. DIFFICILE WITH AN A2A ADENOSINE RECEPTOR AGONIST | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2008-12-18 | — | — | US | disclosed |
| US-20080262001-A1 | a 4-{3-[6-amino-9-(5-ethylcarbamoyl-3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid ester | ADENOSINE THERAPEUTICS, LLC (US) | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080262001-A1 | a 4-{3-[6-amino-9-(5-ethylcarbamoyl-3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid ester | ADORA2A, ADORA3, ADORA2B | ADORA2A 1/4885ADORA3 2/4885ADORA1 4/4885 |
| US-20110166094-A1 | AGONISTS OF A2A ADENOSINE RECEPTORS FOR TREATING RECURRENT TUMOR GROWTH | ADORA2A, ADORA3, ADORA1 | ADORA2A 1/4885ADORA3 2/4885ADORA1 3/4885 |
| US-20080312160-A1 | METHOD OF TREATING ENTERITIS, INTESTINAL DAMAGE, AND DIARRHEA FROM C. DIFFICILE WITH AN A2A ADENOSINE RECEPTOR AGONIST | ADORA2A, ADORA3, GLUL | ADORA2A 1/4885ADORA3 2/4885ADORA1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.